Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.60 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.54 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL4293156 | 1.00 | FOLH1 (0.60) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL3460653 | 0.98 | FOLH1 (0.62) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL1455498 | 0.98 | FOLH1 (0.62) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL1455499 | 0.98 | FOLH1 (0.62) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL27860271 | 0.92 | FOLH1 (0.54) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL2114733 | 0.92 | FOLH1 (0.54) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL2114736 | 0.92 | FOLH1 (0.54) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL30964327 | 0.91 | SLC15A2 (0.62) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL30371073 | 0.91 | SLC15A2 (0.62) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL29532146 | 0.87 | SLC15A2 (0.58) | FOLH1SLC15A2SLC6A5GNPATCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113227124-B | Compounds having affinity substance, cleavage moiety and reactive group for antibody or salts thereof | 味之素株式会社 | 2025-04-08 | — | — | CN | disclosed |
| CN-117377501-A | Radioactive antineoplastic agent | 日本医事物理股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-116829573-A | Compounds or salts thereof, and antibodies derived therefrom | 味之素株式会社 | 2023-09-29 | — | — | CN | disclosed |
| US-11149074-B2 | Azide group-containing Fc protein | AJINOMOTO CO., INC. (JP) | 2021-10-19 | — | — | US | disclosed |
| CN-113227124-A | Compound having affinity substance, cleavable moiety and reactive group for antibody, or salt thereof | 味之素株式会社 | 2021-08-06 | — | — | CN | disclosed |
| CN-112262152-A | Compound having affinity substance, cleavable moiety and reactive group for antibody, or salt thereof | 味之素株式会社 | 2021-01-22 | — | — | CN | disclosed |
| EP-2959896-B1 | USE OF DCP-LA AS REAGENT FOR INHIBITING PHOSPHATASE 1B IN VITRO | NISHIZAKI BIOINFORMATION RES INSTITUTE (JP) | 2020-09-23 | — | — | EP | disclosed |
| US-10597427-B2 | Diabetes-inducible bacterium | AJINOMOTO CO., INC. (JP) | 2020-03-24 | — | — | US | disclosed |
| EP-2641891-B1 | PKC-epsilon ACTIVATOR | NISHIZAKI BIOINFORMATION RES INSTITUTE (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-10251897-B2 | GLUT4 endocytosis inhibitor | NISHIZAKI BIOINFORMATION RESEARCH INSTITUTE (JP) | 2019-04-09 | — | — | US | disclosed |
| EP-2915881-A1 | FIBROTIC NON-HUMAN ANIMAL, AND USE THEREOF | Kyoto University (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-9012500-B2 | PKC-ε activator | NISHIZAKI BIOINFORMATION RESEARCH INSTITUTE (JP) | 2015-04-21 | — | — | US | disclosed |
| US-20150079209-A1 | DIABETES-INDUCIBLE BACTERIUM | AJINOMOTO CO., INC. (JP) | 2015-03-19 | — | — | US | disclosed |
| EP-2832859-A1 | DIABETES-INDUCIBLE BACTERIUM | Ajinomoto Co., Inc. (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-20130331454-A1 | PKC-EPSILON ACTIVATOR | NISHIZAKI BIOINFORMATION RESEARCH INSTITUTE (JP) | 2013-12-12 | — | — | US | disclosed |
| EP-2659892-A1 | CONCOMITANT DRUG FOR IMPROVING COGNITIVE FUNCTION | Nishizaki Bioinformation Research Institute (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-20130274228-A1 | CONCOMITANT DRUG FOR IMPROVING COGNITIVE FUNCTION | NISHIZAKI BIOINFORMATION RESEARCH INSTITUTE (JP) | 2013-10-17 | — | — | US | disclosed |
| EP-2641891-A1 | PKC- ACTIVATOR | Nishizaki Bioinformation Research Institute (JP) | 2013-09-25 | — | — | EP | disclosed |
| US-20120196282-A1 | METHOD OF REGENERATING ELASTIC FIBER AND SCREENING METHOD | NB HEALTH LABORATORY CO. LTD. (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20090233281-A1 | DIAGNOSTIC MARKER FOR ALLERGY | RIKEN (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331454-A1 | PKC-EPSILON ACTIVATOR | PRKCZ, PRKCA, PRKCQ | FOLH1 2397/4885SLC15A2 2445/4885SLC6A5 586/4885 |
| US-10251897-B2 | GLUT4 endocytosis inhibitor | SLC2A4, SLC2A1, SLC2A3 | FOLH1 2798/4885SLC15A2 159/4885SLC6A5 410/4885 |
| US-11149074-B2 | Azide group-containing Fc protein | FCGRT, FCGR1A, FCGR3B | FOLH1 750/4885SLC15A2 2350/4885SLC6A5 1824/4885 |
| US-20130274228-A1 | CONCOMITANT DRUG FOR IMPROVING COGNITIVE FUNCTION | LPCAT1, LPCAT3, CPT1A | FOLH1 643/4885SLC15A2 2591/4885SLC6A5 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.